Holen Sie sich die Stockscreener-App
3.36
0.15%
-0.00
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
What analysts say about Editas Medicine Inc. stockMarket-leading growth rates - jammulinksnews.com
Is Editas Medicine Inc. a good long term investmentExceptional profit margins - Autocar Professional
Editas Medicine Inc. Stock Analysis and ForecastUnrivaled growth potential - jammulinksnews.com
There's Reason For Concern Over Editas Medicine, Inc.'s (NASDAQ:EDIT) Massive 42% Price Jump - simplywall.st
What drives Editas Medicine Inc. stock priceConsistent high-yield stocks - Autocar Professional
What makes Editas Medicine Inc. stock price move sharplyVerified Return Tips - beatles.ru
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Numerous Editas Medicine Insiders Sold Stock: Not A Positive Omen - simplywall.st
Crispr Genomic Cure Market in 2032: A Glimpse Into the Future - openPR.com
Editas Medicine (EDIT) Soars 7.69% on Positive Data - AInvest
Cathie Wood shells out $13.9 million for one high-stakes biotech stock - Yahoo Finance
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - MSN
Restore Health – Therapies that cureTelethon - Ricerca Malattie Genetiche Rare
Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 3000E Index - MarketScreener
Top 10 CRISPR Stocks to Buy Now - Insider Monkey
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? - The Motley Fool
2 Beaten-Down Stocks to Avoid - The Globe and Mail
Gene Editing Market Set to Witness Significant Growth by 2025-2032 | CRISPR Therapeutics, Editas Medicine - openPR.com
Gene editing stocks gain amid FDA's latest leadership change (EDIT:NASDAQ) - Seeking Alpha
Cancer Gene Therapy Market Set to Soar: Breakthrough - openPR.com
From Now to 2032: Unpacking the Genome Editing Market's - openPR.com
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Benzinga
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - AOL.com
Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool
Analysts Set Editas Medicine, Inc. (NASDAQ:EDIT) Price Target at $5.36 - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Position Trimmed by Bank of America Corp DE - MarketBeat
Analysts Offer Predictions for Editas Medicine FY2026 Earnings - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Editas Medicine (EDIT) Unveils Promising Gene Editing Data for B - GuruFocus
Kalkine: Editas Medicine’s In Vivo Gene Editing Progress Unveiled at EHA 2025 with tLNP Approach - Kalkine Media
Breakthrough: New Gene Editing Therapy Achieves 58% Success Rate for Sickle Cell Disease Treatment - Stock Titan
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle - GuruFocus
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hema - GuruFocus
Editas Medicine Reports 58% HBG1/2 Promoter Editing in Non-Human Primates Using High Efficiency tLNP Delivery Method - Nasdaq
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - The Manila Times
Why Is Editas (EDIT) Up 40% Since Last Earnings Report? - Yahoo Finance
4.56%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):